Home Cart Sign in  
Chemical Structure| 28860-95-9 Chemical Structure| 28860-95-9

Structure of Carbidopa
CAS No.: 28860-95-9

Chemical Structure| 28860-95-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Carbidopa is an aromatic-L-amino-acid decarboxylase inhibitor with an IC50 of 29 ± 2 μM.

Synonyms: (S)-(-)-Carbidopa

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Carbidopa

CAS No. :28860-95-9
Formula : C10H14N2O4
M.W : 226.23
SMILES Code : O=C([C@@](NN)(CC1=CC=C(C(O)=C1)O)C)O
Synonyms :
(S)-(-)-Carbidopa
MDL No. :MFCD00069231
InChI Key :TZFNLOMSOLWIDK-JTQLQIEISA-N
Pubchem ID :34359

Safety of Carbidopa

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • decarboxylase

    aromatic-L-amino-acid decarboxylase, IC50:29 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Ruminococcus gnavus 1.5 mM 24 hours Evaluate the inhibitory effect of Carbidopa on PEA production PMC9553188
Enterococcus faecalis 1.5 mM 24 hours Evaluate the inhibitory effect of Carbidopa on PEA production PMC9553188

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Female MF1 mice Mouse marble-burying behavior model Intraperitoneal injection 9 mg/kg Single dose Carbidopa alone reduced marble burying but did not affect runway activity. When co-administered with 5-HTP, it significantly reduced both marble burying and runway activity. PMC1908295
Mice COMT gene-disrupted mice and S-COMT-deficient mice Oral 30 mg/kg Single dose To investigate the pharmacokinetic effects of carbidopa co-administered with L-DOPA in COMT gene-disrupted and S-COMT-deficient mice. Results showed that carbidopa co-administered with L-DOPA significantly increased L-DOPA levels in plasma and peripheral tissues of COMT-KO mice, while significantly decreasing 3-O-methyldopa levels in S-COMT-deficient mice. PMC2807650
Mice Dopamine-deficient mouse model Intraperitoneal injection 12.5 or 25 mg/kg Single administration Carbidopa, when co-administered with L-DOPA, elevates brain dopamine concentrations and induces stereotypy. PMC18425
Mice Dopamine-deficient (DD) mice Intraperitoneal injection 10 mg/kg Single administration Carbidopa was administered with L-DOPA to inhibit peripheral L-aromatic amino acid decarboxylase activity, thereby increasing L-DOPA delivery to the brain and elevating brain dopamine levels. When striatal DA levels exceeded 50% of WT levels, a transition from hyperlocomotion to intense, focused stereotypy was observed in DD mice. PMC56981
Nude mice PNEC tumor xenograft model Intraperitoneal injection 100 mg/kg Once daily for 30 days To evaluate the inhibitory effect of Carbidopa combined with other drugs on PNEC tumor growth, results showed a significant 40% reduction in tumor growth PMC1533883
Mice and rats 8-OH-DPAT-induced hypothermia model Intraperitoneal injection 25 mg/kg Administered 60 min before 5-HTP In mice, carbidopa combined with 5-HTP virtually abolished 8-OH-DPAT-induced hypothermia (93% attenuation); no significant effect was observed in rats PMC1908184
Rats and mice Reserpine-induced Parkinson's disease model Intraperitoneal injection 50 mg/kg Administered 1 hour before Carbidopa combined with L-DOPA reversed reserpine-induced akinesia and hypothermia, and increased striatal dopamine levels PMC1565943

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01766258 Parkinson's Disease Phase 2 Completed - -
NCT01663935 Albinism Ocul... More >>ocutaneous Albinism Less << Phase 2 Recruiting October 2017 United States, Wisconsin ... More >> University of Wisconsin Recruiting Madison, Wisconsin, United States, 53705 Contact: Angie Wealti    608-265-7557    Angie Wealti    Principal Investigator: Michael C Struck, MD Less <<
NCT01468012 Cocaine Dependence Phase 2 Phase 3 Completed - United States, New York ... More >> STARS New York, New York, United States, 10032 Less <<
NCT01468012 - Completed - -
NCT00590122 Parkinson's Disease Phase 4 Completed - United States, Texas ... More >> PDCMDC 6550 Fannin, Suite 1801 Houston, Texas, United States, 77030 Less <<
NCT01636037 Schizophrenia Phase 2 Completed - Canada, Ontario ... More >> Centre for Addiction and Mental Health Toronto, Ontario, Canada, M5T 1R8 Less <<
NCT03735901 Acute Ischemic Stroke ... More >> Stroke Rehabilitation Less << Phase 3 Not yet recruiting December 31, 2022 Switzerland ... More >> Felix Platter Spital Not yet recruiting Basel, Switzerland, 4002 Contact: Stefan Engelter, Prof. MD          Stroke-Center Universitätsspital Basel Not yet recruiting Basel, Switzerland Contact: Philippe Lyrer, Prof.Dr. med          Reha Rheinfelden Not yet recruiting Rheinfelden, Switzerland, 4310 Contact: Thierry Ettlin, Prof. MD Less <<
NCT03665454 Parkinson Disease Phase 1 Recruiting December 31, 2018 United States, Pennsylvania ... More >> Penn State Milton S. Hershey Medical Center Recruiting Hershey, Pennsylvania, United States, 17033 Contact: Bethany L Snyder, MPH    717-531-0003 ext 281277    bsnyder2@pennstatehealth.psu.edu    Contact: Mechelle Lewis, PhD    717-531-0003 ext 281166    mlewis5@pennstatehealth.psu.edu Less <<
NCT01515410 Parkinson's Disease ... More >> Motor Fluctuations Less << Phase 2 Completed - United States, Alabama ... More >> Birmingham, Alabama, United States United States, Arkansas Little Rock, Arkansas, United States United States, California Long Beach, California, United States United States, Illinois Chicago, Illinois, United States United States, Michigan Bingham Farms, Michigan, United States United States, Ohio Cincinnati, Ohio, United States United States, Texas Dallas, Texas, United States Less <<
NCT00139867 Parkinson's Disease Phase 3 Completed - United States, Wisconsin ... More >> Schwarz Milwaukee, Wisconsin, United States Less <<
NCT02289729 - Completed - Spain ... More >> Site Reference ID/Investigator# 134791 Almeria, Spain, 04009 Site Reference ID/Investigator# 128564 Barcelona, Cataluna, Spain, 08907 Site Reference ID/Investigator# 136824 Barcelona, Spain, 08003 Site Reference ID/Investigator# 136823 Barcelona, Spain, 08035 Site Reference ID/Investigator# 128571 Barcelona, Spain, 08036 Site Reference ID/Investigator# 136826 Barcelona, Spain, 08041 Site Reference ID/Investigator# 128566 Barcelona, Spain, 08208 Site Reference ID/Investigator# 134792 Burgos, Spain, 09006 Site Reference ID/Investigator# 128568 Caceres, Spain, 10003 Site Reference ID/Investigator# 128570 Caceres, Spain, 10003 Site Reference ID/Investigator# 128556 Cadiz, Andalucia, Spain, 11009 Site Reference ID/Investigator# 128560 Cadiz, Andalucia, Spain, 11009 Site Reference ID/Investigator# 128584 Cartagena, Murcia, Spain, 30200 Site Reference ID/Investigator# 128578 Elche, Alicante, Spain, 03203 Site Reference ID/Investigator# 128558 Espana, Canarias, Spain, 35016 Site Reference ID/Investigator# 134794 Ferrol, Spain, 15405 Site Reference ID/Investigator# 128561 Granada, Andalucia, Spain, 18013 Site Reference ID/Investigator# 147524 Las Palmas de Gran Canaria, Spain, 35010 Site Reference ID/Investigator# 128562 Palma de Mallorca, Balearas, Spain, 07010 Site Reference ID/Investigator# 128565 Pamplona, Spain, 31008 Site Reference ID/Investigator# 128569 Pamplona, Spain, 31008 Site Reference ID/Investigator# 134795 Santa Cruz de Tenerife, Spain, 38010 Site Reference ID/Investigator# 136822 Seville, Spain, 41009 Site Reference ID/Investigator# 128583 Valencia, Spain, 46026 Site Reference ID/Investigator# 134793 Valladolid, Spain, 47005 Site Reference ID/Investigator# 128555 Zaragoza, Aragon, Spain, 50010 Site Reference ID/Investigator# 128557 Zaragoza, Aragon, Spain, 50010 Less <<
NCT01515410 - Completed - -
NCT01411137 Parkinson's Disease Phase 3 Completed - United States, Alabama ... More >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35233 United States, California Coastal Neurological Medical Group La Jolla, California, United States, 92037 The Parkinson's Institute Sunnyvale, California, United States, 94085 United States, Florida Renstar Medical Research Ocala, Florida, United States, 34471 United States, Michigan Quest Research Institute Bingham Farms, Michigan, United States, 48025 United States, Nevada University of Nevada School of Medicine Las Vegas, Nevada, United States, 89102 United States, New York Parkinson's Disease and Movement Disorders Center of Long Island Commack, New York, United States, 11725 United States, Wisconsin Wisconsin Institute for Neurologic and Sleep Disorders Milwaukee, Wisconsin, United States, 53233 Less <<
NCT01411137 - Completed - -
NCT02169414 - Completed - -
NCT00789672 Amblyopia Phase 2 Completed - United States, Maryland ... More >> Wilmer Eye Institute Baltimore, Maryland, United States, 21287 Less <<
NCT02169414 Parkinson's Disease (PD) Phase 1 Completed - France ... More >> BIOTRIAL Rennes, France, F-35034 Less <<
NCT00789672 - Completed - -
NCT00366184 - Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01479127 Advanced Parkinson's Disease Phase 2 Completed - -
NCT02726386 Parkinson's Disease Phase 2 Active, not recruiting August 2021 -
NCT00713583 - Completed - -
NCT01479127 - Completed - -
NCT01533116 Parkinson Disease Phase 1 Completed - Canada, Quebec ... More >> Algorithme Pharma Inc. Mount-Royal, Quebec, Canada, H3P 3P1 Less <<
NCT02633839 Smoking Phase 1 Completed - United States, Florida ... More >> Site 001 Daytona Beach, Florida, United States, 32117 United States, Texas Site 002 Dallas, Texas, United States, 75247 Less <<
NCT01533116 - Completed - -
NCT03055936 Healthy Volunteers Phase 1 Completed - Germany ... More >> Nuvisan Pharma Services Neu-Ulm, Germany, 89231 Less <<
NCT00713583 Cocaine Dependence Phase 2 Completed - United States, Texas ... More >> The University of Texas Health Science Center at Houston Houston, Texas, United States, 77030 Less <<
NCT02346630 Stroke Phase 4 Withdrawn(We didn't receive th... More >>e expected funding to support the study.) Less << March 2017 United States, Massachusetts ... More >> Spaulding Rehabilitation Hospital Charlestown, Massachusetts, United States, 02129 Less <<
NCT00141518 Advanced Idiopathic Parkinson'... More >>s Disease Less << Phase 4 Completed - -
NCT00143026 Parkinson's Disease Phase 4 Completed - Australia ... More >> Royal Adelaide Hospital Adelaide, Australia Watkins Medical Center Brisbane, Australia Central Coast Neuroscience Research Gosford, Australia Heidelberg Repatriation Hospital Melbourne, Australia Monash Medical Centre Melbourne, Australia Sir Charles Gairdner Hospital Perth, Australia Concord Hospital Sydney, Australia Southern Neurology, St. George Private Hospital Sydney, Australia Westmead Hospital Sydney, Australia Philippines St. Luke's Medical Centre Manila, Philippines University of Santo Tomas Hospital Manila, Philippines Taiwan Chang Gung Memorial Hospital Linkou, Taiwan Kaohsiung Medical University, Chung-Ho Memorial Hospital Linkou, Taiwan National Taiwan University Hospital Linkou, Taiwan Thailand King Chulalongkorn Memorial Hospital Bangkok, Thailand Maharaj Nakorn Chiangmai Hospital Bangkok, Thailand Siriraj Hospital Bangkok, Thailand Pharmongkutklao Army Hospital Bankok, Thailand Less <<
NCT02763137 Parkinson Disease Phase 2 Completed - Italy ... More >> Irccs San Raffaele Pisana Rome, Italy, 00163 Less <<
NCT01486628 Parkinson's Disease Phase 1 Completed - Israel ... More >> Hadassah Medical Center Jerusalem, Israel Less <<
NCT00279825 Idiopathic Parkinson's Disease Phase 2 Completed - United States, Michigan ... More >> Quest Research Institute Bingham Farms, Michigan, United States, 48025 United States, Oregon Oregon Health Sciences University - Parkinson's Center of Oregon Portland, Oregon, United States, 97239 Less <<
NCT00253084 Parkinson's Disease Phase 2 Completed - United States, Illinois ... More >> Site 1 Chicago, Illinois, United States, 60612 United States, South Carolina Site 2 Charleston, South Carolina, United States, 29425 Less <<
NCT03602924 - Recruiting December 31, 2018 Spain ... More >> Hospital Universitari Vall d'Hebron Recruiting Barcelona, Spain, 08035 Contact: Oriol de Fabregues, MD, PhD    00 34 934894258 ext 4258    odfabregues@vhebron.net    Contact: Inmaculada Fuentes Camps, MD    00 34 4894113 ext 4881    usic@vhir.org Less <<
NCT00125567 Idiopathic Parkinson's Disease Phase 4 Completed - Denmark ... More >> Aalborg Hospital Aalborg, Denmark, DK-9000 Aalborg Bispebjerg Hospital Copenhagen, Denmark Århus Kommunehospital Nørrebrogade 44, Denmark, 8000 Finland South Karelia Central Hospital Lappeenranta, Finland Tampere University Hospital Tampere, Finland, 33521 Tampere Germany Parkinson Klinik Bad Nauheim Bad Nauheim, Germany, 61231 Bad Nauheim Neurologische Klinik Bad Neustadt Bad Neustadt, Germany, 97616 Bad Neustadt Neurologische Klinik der Universitat Dusseldorf Duesseldorf, Germany, 40225 Duesseldorf Allgemeines Krankenhaus Harburg Hamburg, Germany, 21075 Hamburg Praxis Drs Lang, Krauss, Schreiber Ulm, Germany, 89073 Ulm Ireland Mater Private Hospital Dublin, Ireland, Dublin 7 Sweden Universitetssjukhuset MAS Malmö, Sweden, SE-205 02 Läkarhuset Vällingby Vällingby, Sweden, SE-162 68 United Kingdom Movement Disorder Services Chertsey, Surrey, United Kingdom, KT16 0QA University Hospital of Wales Cardiff, Wales, United Kingdom, CF14 4XW Glan Clwyd Hospital Rhyl, Wales, United Kingdom, CF14 4XW Frenchay Hospital Bristol, United Kingdom, BS16 1LE Leigh Infirmary Leigh, United Kingdom, WN7 1HS Southampton General Hospital Southampton, United Kingdom, SO16 6YD Less <<
NCT03235037 Angelman Syndrome Not Applicable Enrolling by invitation November 1, 2019 -
NCT00203177 Parkinson's Disease Phase 3 Completed - United States, California ... More >> Margolin Brain Institute Fresno, California, United States, 93720 United States, Georgia Emory University Atlanta, Georgia, United States, 30329 United States, Illinois Rush - Presbyterian St. Luke's Medical Center Chicago, Illinois, United States, 60612 United States, Nebraska Creighton University Omaha, Nebraska, United States, 68131 United States, New York Long Island Jewish Medical Center New Hyde Park, New York, United States, 11040 University of Rochester Rochester, New York, United States, 14642 United States, Pennsylvania Pennsylvania Hospital Philadelphia, Pennsylvania, United States, 19107 Canada, Quebec CHUM-Hotel-Dieu Montreal, Quebec, Canada, H2w1T8 Less <<
NCT01130493 - Completed - -
NCT01130493 Parkinson's Disease Phase 3 Completed - United States, California ... More >> Margolin Brain Institute Fresno, California, United States, 93720 The Parkinson's Institute in Sunnyvale Sunnyvale, California, United States, 94085 United States, Florida UM Movement Disorders Center Miami, Florida, United States, 33136 Charlotte Neurological Services Port Charlotte, Florida, United States, 33980 USF Parkinson's and Movement Disorders Center Tampa, Florida, United States, 33606 United States, Michigan Quest Research Institute Bingham Farms, Michigan, United States, 48025 United States, Nevada University Health Systems Las Vegas, Nevada, United States, 89102 United States, New York Parkinson's Disease and Movement Disorders Center of Long Island Commack, New York, United States, 11725 Kingston Neurological Associates Kingston, New York, United States, 12401 United States, Ohio University Neurology, Inc Cincinnati, Ohio, United States, 45219 United States, Virginia Sentara Neurological Associates Virginia Beach, Virginia, United States, 23456 United States, Washington Booth Gardner Parkinson's Care Center Kirkland, Washington, United States, 98034 France Hôpital Gabriel Montpied-Service de Neurologie A- Clermont-Ferrand Cedex 1, France, 63003 Service de neurologie-Hôpital de la Timone- Marseille, France, 13385 Germany Praxis für Neurologie, Psychiatrie und Psychotherapie Achim Achim, Germany, 28832 Praxis Dres. Bitter/Schumann Bochum, Germany, 44805 Klinikum rechts der Isar der Technischen Universität München München, Germany, 81675 Klinik für Neurologie, Stadtroda Stadtroda, Germany, 07646 RKU, Neurologische Klinik der Universität Ulm Ulm, Germany, 89081 Italy Casa di Cura Villa Margherita Arcugnano, Italy, 36057 San Raffaele Cassino, San Raffaele Cassino, Cassino, Italy, 03043 Dipartimento di Oncologia e Neuroscienze, Università G. D'Annunzio Chieti, Italy, 66013 Ospedale della Misericordia Grosseto, Italy, 58100 IRCCS San Raffaele Pisana Roma, Italy, 163 Less <<
NCT03462043 Parkinson Phase 3 Withdrawn(Decision to change t... More >>he study design) Less << December 30, 2018 Italy ... More >> 91601 Roma, Italy, 00163 Less <<
NCT00914602 Parkinson's Disease Phase 1 Phase 2 Completed - United States, Arizona ... More >> XenoPort Investigational Site Peoria, Arizona, United States, 85381 United States, Michigan XenoPort Investigational Site Bingham Farms, Michigan, United States, 48025 Less <<
NCT01883505 Parkinson's Disease Phase 2 Completed - Israel ... More >> Hadassah Medical Center Jerusalem, Israel Rabin Medical Center Petah Tikva, Israel Tel Aviv Medical Center Tel Aviv, Israel Less <<
NCT03496870 Parkinson Disease Phase 1 Active, not recruiting November 1, 2018 United States, California ... More >> Neurocrine Clinical Site Glendale, California, United States, 91206 Neurocrine Clinical Site Long Beach, California, United States, 90806 United States, Michigan Neurocrine Clinical Site Farmington Hills, Michigan, United States, 48334 Less <<
NCT03576638 Parkinson Disease Phase 2 Not yet recruiting January 2019 -
NCT01070628 Parkinson's Disease Phase 1 Completed - Finland ... More >> Phase I Unit, Orion Pharma Espoo, Finland, 02101 Less <<
NCT00141518 - Completed - -
NCT00955045 Parkinson's Disease Phase 2 Phase 3 Completed - United States, New Jersey ... More >> 48 Centers in the US and 4 in Canada Princeton, New Jersey, United States, 08540 Less <<
NCT00562198 Parkinson′s Disease Phase 2 Terminated(Illogistical result... More >>s found in interim evaluation.) Less << - Finland ... More >> Helsinki University Hospital, Department of Neurology Helsinki, Finland, 00029 Oulu University Hospital, Department of Neurology Oulu, Finland, 90220 Porin Lääkäritalo Pori, Finland, 28100 FinnMedi Tutkimus Oy Tampere, Finland, 33520 CRST Turku, Finland, 20520 Less <<
NCT02763839 Parkinson's Disease Phase 1 Completed - Portugal ... More >> Human Pharmacology Unit - BIAL - Portela & Ca, S.A. S. Mamede do Coronado, Portugal, 4745-457 Less <<
NCT02452606 Parkinson Disease ... More >> Sleep Disorders Less << Not Applicable Unknown May 2017 Korea, Republic of ... More >> Asan Medical Center Recruiting Seoul, Korea, Republic of, 05505 Contact: Sun Ju Chug, Professor    82-2-3010-3988    sunjubrain@gmail.com Less <<
NCT02554734 Parkinson's Disease Phase 1 Completed - Finland ... More >> Clinical Research Services Turku CRST Turku, Finland Less <<
NCT02169453 Parkinson's Disease (PD) Phase 1 Completed - Canada, Quebec ... More >> Algorithme Pharma Inc Mount-Royal, Quebec, Canada, H3P 3P1 Less <<
NCT02169453 - Completed - -
NCT02169479 Parkinson's Disease (PD) Phase 1 Completed - Canada, Quebec ... More >> Algorithme Pharma Inc Mount-Royal, Quebec, Canada, H3P 3P1 Less <<
NCT00906828 Parkinson Disease Phase 4 Completed - Sweden ... More >> Uppsala University Hospital Uppsala, Sweden, 75646 Less <<
NCT03266965 Multiple Sclerosis Phase 1 Recruiting March 20, 2019 United States, Florida ... More >> University of Miami Recruiting Miami, Florida, United States, 33136 Contact: Kottil W Rammohan, M.D    305-246-2279    krammohan@med.miami.edu    Contact: Leticia Tornes, M.D.    305-246-2279    ltornes@med.miami.edu    Principal Investigator: Kottil W Rammohan, M.D Less <<
NCT02549092 Parkinson's Disease (PD) Phase 3 Recruiting January 2, 2020 -
NCT01754129 - Completed - -
NCT02169479 - Completed - -
NCT01533077 - Completed - -
NCT02774564 Parkinson's Disease Phase 1 Completed - Portugal ... More >> Human Pharmacology Unit S. Mamede do Coronado, Portugal, 4745-457 Less <<
NCT02448914 Parkinson's Disease Phase 1 Completed - Sweden ... More >> Clinical Trial Consultants AB Uppsala, Sweden, SE-75185 Less <<
NCT01754129 - Completed - -
NCT00134966 Parkinson's Disease Phase 3 Completed - -
NCT02312232 Parkinson's Disease Phase 1 Completed - Finland ... More >> CRST Turku, Finland, 20520 Less <<
NCT00460954 - Completed - Canada, Ontario ... More >> Local Institution Toronto, Ontario, Canada, M5V 2T3 Less <<
NCT01533077 Parkinson Disease Phase 1 Completed - Canada, Quebec ... More >> Algorithme Pharma Inc. Mount-Royal, Quebec, Canada, H3P 3P1 Less <<
NCT02448914 - Completed - -
NCT00335153 Advanced Parkinson's Disease Phase 3 Completed - -
NCT00456586 Parkinson's Disease Phase 2 Completed - United States, New Jersey ... More >> Contact Kyowa Pharmacuetical Inc. Princeton, New Jersey, United States, 08540 Less <<
NCT00869791 Parkinson's Disease Phase 2 Completed - United States, California ... More >> IMPAX Laboratories Hayward, California, United States, 94544 Less <<
NCT01683253 Impulse Control Disorder Phase 4 Completed - -
NCT00869791 - Completed - -
NCT00335153 - Completed - -
NCT01725802 Parkinson's Disease Phase 1 Phase 2 Completed - Israel ... More >> Hadassah Medical Center Jerusalem, Israel Less <<
NCT00432393 Nonarteritic Anterior Ischemic... More >> Optic Neuropathy Less << Phase 4 Completed - Iran, Islamic Republic of ... More >> Ophthalmic research center Tehran, Iran, Islamic Republic of, 1666694516 Less <<
NCT00357994 Advanced Parkinson's Disease Phase 3 Completed - United States, California ... More >> Site Reference ID/Investigator# 45719 Los Angeles, California, United States, 90033 United States, Colorado Site Reference ID/Investigator# 45718 Englewood, Colorado, United States, 80113 United States, District of Columbia Site Reference ID/Investigator# 45722 Washington, District of Columbia, United States, 20007 United States, Florida Site Reference ID/Investigator# 45721 Bradenton, Florida, United States, 34205 Site Reference ID/Investigator# 45705 Gainesville, Florida, United States, 32610 United States, Maryland Site Reference ID/Investigator# 45740 Baltimore, Maryland, United States, 21201 United States, Missouri Site Reference ID/Investigator# 45739 St. Louis, Missouri, United States, 63110 United States, Vermont Site Reference ID/Investigator# 45703 Burlington, Vermont, United States, 05401 Germany Site Reference ID/Investigator# 44970 Bochum, Germany, 44791 Site Reference ID/Investigator# 44971 Bremerhaven, Germany, 27574 Site Reference ID/Investigator# 44973 Dresden, Germany, 01307 Site Reference ID/Investigator# 44965 Hanover, Germany, 30625 Site Reference ID/Investigator# 44964 Kiel, Germany, 24105 Site Reference ID/Investigator# 44966 Marburg, Germany, 35033 Site Reference ID/Investigator# 44968 Tuebingen, Germany, 72076 Less <<
NCT00660387 Advanced Parkinson's Disease Phase 3 Completed - United States, Alabama ... More >> Site Reference ID/Investigator# 45931 Birmingham, Alabama, United States, 35222 United States, California Site Reference ID/Investigator# 45910 Fountain Valley, California, United States, 92708 Site Reference ID/Investigator# 45925 Oceanside, California, United States, 92056 United States, Florida Site Reference ID/Investigator# 45912 Port Charlotte, Florida, United States, 33890 United States, Illinois Site Reference ID/Investigator# 45935 Chicago, Illinois, United States, 60611 United States, Kentucky Site Reference ID/Investigator# 45930 Lexington, Kentucky, United States, 40536 United States, New York Site Reference ID/Investigator# 45934 New York, New York, United States, 10032 United States, North Carolina Site Reference ID/Investigator# 45929 Winston-Salem, North Carolina, United States, 27157 United States, Ohio Site Reference ID/Investigator# 45908 Cincinnati, Ohio, United States, 45267 Site Reference ID/Investigator# 45922 Cleveland, Ohio, United States, 44195-0001 United States, Washington Site Reference ID/Investigator# 45915 Kirkland, Washington, United States, 98034 New Zealand Site Reference ID/Investigator# 45904 Auckland, New Zealand, 1010 Site Reference ID/Investigator# 45902 Christchurch, New Zealand, 8011 Site Reference ID/Investigator# 45905 Hamilton, New Zealand, 3204 Less <<
NCT02873351 Age-related Macular Degenerati... More >>on Less << Phase 2 Suspended(Decided to do studie... More >>s in patients with AMD rather than study surrogate markers in patients without AMD.) Less << December 2020 United States, Arizona ... More >> Robert W Snyder, MD, PhD, PC Tucson, Arizona, United States, 85712 Less <<
NCT01437293 Cocaine Abuse Phase 1 Completed - United States, New York ... More >> New York State Psychiatric Institute New York, New York, United States, 10032 Less <<
NCT00357994 - Completed - -
NCT00360568 Dyskinesias P... More >>arkinson's Disease Severe Motor Fluctuations Less << Phase 3 Completed - United States, Alabama ... More >> Site Reference ID/Investigator# 45869 Birmingham, Alabama, United States, 35222 United States, California Site Reference ID/Investigator# 45834 Fountain Valley, California, United States, 92708 Site Reference ID/Investigator# 45854 Los Angeles, California, United States, 90033 Site Reference ID/Investigator# 45856 Oceanside, California, United States, 92056 United States, District of Columbia Site Reference ID/Investigator# 45859 Washington, District of Columbia, United States, 20007 United States, Florida Site Reference ID/Investigator# 45857 Bradenton, Florida, United States, 34205 Site Reference ID/Investigator# 45863 Gainesville, Florida, United States, 32610 Site Reference ID/Investigator# 45836 Port Charlotte, Florida, United States, 33890 United States, Illinois Site Reference ID/Investigator# 45874 Chicago, Illinois, United States, 60611 United States, Kentucky Site Reference ID/Investigator# 45868 Lexington, Kentucky, United States, 40536 United States, Maryland Site Reference ID/Investigator# 45862 Baltimore, Maryland, United States, 21201 United States, Missouri Site Reference ID/Investigator# 45861 St. Louis, Missouri, United States, 63110 United States, New York Site Reference ID/Investigator# 45873 New York, New York, United States, 10032 United States, Ohio Site Reference ID/Investigator# 45878 Cincinnati, Ohio, United States, 45267 Site Reference ID/Investigator# 45850 Cleveland, Ohio, United States, 44195-0001 United States, Vermont Site Reference ID/Investigator# 45887 Burlington, Vermont, United States, 05401 Germany Site Reference ID/Investigator# 45828 Bochum, Germany, 44791 Site Reference ID/Investigator# 45829 Bremerhaven, Germany, 27574 Site Reference ID/Investigator# 45825 Hanover, Germany, 30625 Site Reference ID/Investigator# 54402 Tuebingen, Germany, 72076 New Zealand Site Reference ID/Investigator# 45884 Auckland, New Zealand, 1010 Site Reference ID/Investigator# 45885 Hamilton, New Zealand, 3204 Less <<
NCT00415844 Healthy Phase 1 Completed - Germany ... More >> Novartis Investigative Site Nuernberg, Germany Less <<
NCT00360568 - Completed - -
NCT00660673 Advanced Parkinson's Disease Phase 3 Active, not recruiting September 30, 2020 -
NCT00415922 Healthy Phase 1 Completed - Germany ... More >> Novartis Investigative Site Nuernberg, Germany Less <<
NCT00415740 Healthy Phase 1 Completed - Germany ... More >> Novartis Investigative Site Nuernberg, Germany Less <<
NCT02577523 Parkinson's Disease Phase 2 Unknown March 2017 United States, Illinois ... More >> Northwestern University Chicago, Illinois, United States, 60611 United States, Michigan QUEST Research Institute Farmington Hills, Michigan, United States, 48334 Austria Medical University Innsbruck Innsbruck, Austria, A- 4060 Israel Rabin Medical Center Petah Tikva, Israel, 4941492 Chaim Sheba Medical Center Ramat Gan, Israel, 56520 Sourasky Medical Center Tel Aviv, Israel, 64239 Italy IRCCS San Raffaele Pisana Rome, Italy, 00163 Fondazione Ospedale San Camillo - I.R.C.C.S. Venice, Italy, 30126 Less <<
NCT00660387 - Completed - -
NCT00601978 Parkinson's Disease Phase 4 Withdrawn(Business decision br... More >>and strategy; no patients enrolled) Less << - -
NCT02799381 Parkinson's Disease (PD) Phase 3 Recruiting January 31, 2020 United States, Florida ... More >> Parkinson's Disease Treatment Center of Southwest Florida /ID# 150095 Completed Port Charlotte, Florida, United States, 33980 United States, Texas Central Texas Neurology Consul /ID# 150088 Active, not recruiting Round Rock, Texas, United States, 78681 Finland Helsinki Univ Central Hospital /ID# 151214 Recruiting Helsinki, Finland, 00290 Oulun yliopistollinen sairaala /ID# 150947 Recruiting Oulu, Finland, 90220 Greece University General Hospital "Attikon" /ID# 200761 Not yet recruiting Athens, Attiki, Greece, 12462 Mediterraneo Hospital /ID# 150955 Recruiting Glyfada, Greece, 16675 University General Hospital of Heraklion "PA.G.N.I" /ID# 150956 Recruiting Heraklion, Greece, 71110 University Hospital of Ioannin /ID# 150954 Recruiting Ioannina, Greece, 45500 Hungary Klinikai Konzpont,onkoterapias Intezet /ID# 170116 Recruiting Pécs, Pecs, Hungary, 7624 II.Sz.Gyermekgyogyaszati Klinika,Neuro-onkologia /ID# 170117 Not yet recruiting Budapest, Hungary, 1085 Szegedi Tudomanyegyetem /ID# 170115 Recruiting Szeged, Hungary, 6720 Italy Policlinico Universitario Campus Bio-Medico /ID# 150846 Recruiting Rome, Lazio, Italy, 00128 A.O. Univ. Ospedali Riuniti /ID# 150853 Not yet recruiting Ancona, Marche, Italy, 60126 A.O.U Sant'Anna di Ferrara /ID# 202497 Not yet recruiting Ferrara, Italy, 44124 Azienda USL Toscana Centro /ID# 150770 Recruiting Florence, Italy, 50012 Seconda Universita' di Napoli /ID# 150851 Recruiting Naples, Italy, 80138 Policlinico Tor Vergata /ID# 151167 Recruiting Rome, Italy, 00133 Slovakia Univerzitna nemocnica L. Pasteura /ID# 150146 Recruiting Košice - Sever, Kosicky Kraj, Slovakia, 040 01 Univerzitna nemocnica Martin /ID# 150145 Recruiting Martin, Zilinsky Kraj, Slovakia, 036 01 Univerzitna Nemocnica Bratislava /ID# 150144 Recruiting Bratislava, Slovakia, 826 06 Univerzitna Nemocnica Bratislava /ID# 150171 Recruiting Bratislava, Slovakia, 826 06 Spain Hospital Regional Universitari /ID# 171485 Recruiting Málaga, Malaga, Spain, 29010 Hospital Universitario Cruces /ID# 203807 Not yet recruiting Barakaldo, Spain, 48903 Hospital General Univ de Elche /ID# 150154 Recruiting Elche, Spain, 03202 Hospital Univ de la Princesa /ID# 150157 Recruiting Madrid, Spain, 28006 Hospital General Universitario Gregorio Maranon /ID# 150155 Not yet recruiting Madrid, Spain, 28007 Hospital Univ Ramon y Cajal /ID# 150152 Recruiting Madrid, Spain, 28034 Hospital Universitario Infanta /ID# 159696 Recruiting Madrid, Spain, 28702 Hospital Universitario Virgen Macarena /ID# 158861 Recruiting Sevilla, Spain, 41009 Hospital Virgen de la Salud /ID# 166297 Recruiting Toledo, Spain, 45005 Less <<
NCT02605434 Parkinson's Disease Phase 3 Active, not recruiting October 2018 -
NCT00219284 Parkinson's Disease With End o... More >>f Dose Wearing Off Less << Phase 4 Completed - -
NCT00219284 - Completed - -
NCT00415831 Healthy Phase 1 Completed - Germany ... More >> Novartis Investigative Site Nuernberg, Germany Less <<
NCT02096601 Parkinson's Disease Phase 1 Phase 2 Unknown - United States, Michigan ... More >> Henry Ford West Bloomfield Hospital West Bloomfield, Michigan, United States, 48034 Israel Hadassah Medical Center Not yet recruiting Jerusalem, Israel Tel Aviv Medical Center Not yet recruiting Tel Aviv, Israel Less <<
NCT00099268 Parkinson's Disease Phase 3 Completed - -
NCT00983814 Attention Deficit Hyperactivit... More >>y Disorder Less << Phase 2 Completed - United States, New York ... More >> VA New York Harbor Healthcare System/New York University Langone Medical Center New York, New York, United States, 10010 Less <<
NCT00547911 Parkinson Disease ... More >> Multiple System Atrophy Autonomic Nervous System Diseases Less << Phase 1 Phase 2 Terminated(Study terminated du... More >>e to contamination droxidopa) Less << - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00099268 - Completed - -
NCT00642356 - Terminated(slow enrollment) - -
NCT00547911 - Terminated(Study terminated du... More >>e to contamination droxidopa) Less << - -
NCT00558337 Parkinson's Disease Phase 2 Completed - Argentina ... More >> Fundacion Alfredo Thomson Buenos Aires, Argentina Hospital Posadas Buenos Aires, Argentina Hospital Ramos Mejía Buenos Aires, Argentina Hospital Sirio Libanés Buenos Aires, Argentina Instituto Frenopático Buenos Aires, Argentina nstituto INEBA Buenos Aires, Argentina Policlínica Bancaria Buenos Aires, Argentina Fundación Rosarina de Neuro-Rehabilitación Rosario, Argentina Hospital San Bernardo Salta, Argentina Less <<
NCT01484990 Parkinson Disease Phase 1 Completed - -
NCT01323374 Fibromyalgia Phase 2 Completed - United Kingdom ... More >> Rheumatology Department; Barnsley Hospital NHS Foundation Trust Barnsley, United Kingdom, S75 2EP MAC UK Neuroscience Liverpool, United Kingdom, L18 1HQ Academic Dept of Rheumatology, Kings College London London, United Kingdom, SE5 9RJ MAC UK Neuroscience Manchester, United Kingdom, M32 0UT Musculoskeletal Department; Freeman Hospital Newcastle Upon Tyne, United Kingdom, NE7 7DN Rheumatology Department, Poole Hospital NHS Trust Poole, United Kingdom, BH15 2JB Clinical Trials Unit; Main Hospital; Salford Rooyal NHS Foundation Trust Salford, United Kingdom, M6 8HD Less <<
NCT02812394 Parkinson Disease Phase 1 Completed - United States, Texas ... More >> Site #001 Dallas, Texas, United States, 75247 Less <<
NCT03022318 Age-related Macular Degenerati... More >>on Less << Phase 2 Recruiting February 2019 United States, Arizona ... More >> Robert W Snyder, MD, PhD, PC Recruiting Tucson, Arizona, United States, 85712 Contact: Timothy C Fagan, MD    520-404-5801    tcfaganmd@gmail.com    Contact: Robert W Snyder, MD    5206616516    rsnyder781@gmail.com Less <<
NCT00391898 Parkinson's Disease Phase 4 Completed - Spain ... More >> Hospital Universitario Principe de Asturias Alcalá de Henares, Madrid, Spain, 28805 Fundación Hospital de Alcorcón Alcorcón (Madrid, Spain, 28922 Hospital General de Alicante Alicante, Spain, 03010 Centro Médico Teknon Barcelona, Spain, 08022 Hospital de la Santa Creu i de Sant Pau Barcelona, Spain, 08025 Hospital Vall d'Hebron Barcelona, Spain, 08025 Hospital Clínic i Provincial de Barcelona Barcelona, Spain, 08036 Corporació Sanitària Parc Taulí Sabadell Barcelona, Spain, 08208 Hospital General Yagüe Burgos, Spain, 09005 Hospital Universitario Virgen de las Nieves Granada, Spain, 18012 Hospital Universitari Bellvitge Princeps d'Espanya L'Hospitalet de Llobregat , Barcelona, Spain, 08907 Hospital Juan Canalejo La Coruña, Spain, 15002 Clínica Ruber Madrid, Spain, 28006 Hospital General Universitario Gregorio Marañon Madrid, Spain, 28007 Fundación Jiménez Díaz Madrid, Spain, 28040 Hospital Clínico San Carlos Madrid, Spain, 28040 Hospital 12 de Octubre Madrid, Spain, 28041 Hospital Universitario La Paz Madrid, Spain, 28046 Universitaria de Navarra Pamplona, Spain, 31008 Policlínica Gipuzkoa San Sebastian, Spain, 20009 Hospital General de Catalunya Sant Cugat del Valles, Barcelona, Spain, 08195 Hospital Universitario Virgen del Rocio Sevilla, Spain, 41013 Hospital Mutua de Terrassa Terrassa, Barcelona, Spain, 08221 Hospital Universitario de la Fe Valencia, Spain, 46009 Hospital Clínico Universitario de Valencia Valencia, Spain, 46010 Hospital Gral. de Valencia Valencia, Spain, 46014 Less <<
NCT00391898 - Completed - -
NCT01736176 Advanced Parkinson's Disease Phase 3 Completed - -
NCT03197493 Macula; Degeneration ... More >> Retina Less << Phase 2 Recruiting March 31, 2019 United States, Arizona ... More >> Robert W Snyder, MD, PhD, PC Recruiting Tucson, Arizona, United States, 85712 Contact: Timothy C Fagan, MD    520-404-5801    tcfaganmd@gmail.com    Contact: Robert W Snyder, MD    5206616516    rsnyder781@gmail.com Less <<
NCT01736176 - Completed - -
NCT02116465 Fasted State Phase 1 Completed - Bulgaria ... More >> Department of Clinical Pharmacology Sofia, Bulgaria, 1527 Less <<
NCT03451500 Age Related Macular Degenerati... More >>on Less << Phase 2 Recruiting March 2020 United States, Arizona ... More >> Robert W Snyder, MD, PhD, PC Recruiting Tucson, Arizona, United States, 85712 Contact: Timothy C Fagan, MD    520-404-5801    tcfaganmd@gmail.com    Contact: Robert W Snyder, MD    5206616516    rsnyder781@gmail.com Less <<
NCT02553265 Dysautonomia, Familial ... More >> Baroreflex Failure Syndrome Less << Phase 2 Recruiting June 2019 United States, New York ... More >> NYU Langone Medical Center, Dyautonomia Center, Suite 9Q Recruiting New York, New York, United States, 10016 Contact: Jose M Martinez, MA    212-263-7225    jose.martinez@nyumc.org    Contact: Lucy Norcliffe-Kaufmann, PhD    212 263 7225 ext 37489    norcll01@nyumc.org    NYU Medical Center Recruiting New York, New York, United States, 10016 Contact: Jose Martinez, MA    212-263-7225    jose.martinez@nyumc.org    Principal Investigator: Horacio Kaufmann, MD          Principal Investigator: Lucy J Norcliffe-Kaufmann, PhD Less <<
NCT03362879 - Recruiting January 31, 2019 -
NCT00642356 Parkinson's Disease Phase 4 Terminated(slow enrollment) - United States, Arizona ... More >> Xenoscience, Inc Phoenix, Arizona, United States, 85004 United States, California South Coast Health Center Aliso Viejo, California, United States, 92656 University of California Irvine, California, United States, 92697 Coastal Neurological Medical Group, Inc La Jolla, California, United States, 92037 United States, District of Columbia Georgetown University Hospital Washington, District of Columbia, United States, 20007 United States, Florida Sunrise Clinical Research, Inc Hollywood, Florida, United States, 33021 Charlotte Neurological Services Port Charlotte, Florida, United States, 33952 United States, Kansas Cotton O'Neil Clinic Topeka, Kansas, United States, 66606 United States, Maryland University of Maryland School of Medicine Baltimore, Maryland, United States, 21201 United States, Missouri Neurology, Inc Columbia, Missouri, United States, 65201 Dr. John's Mercy Medical Center St. Louis, Missouri, United States, 63141 United States, Nebraska Creighton U Medical Center, Dept of Neurology Omaha, Nebraska, United States, 68131 United States, New York Parkinson's Disease & Movement Disorders Commack, New York, United States, 11725 Central New York Research Corporation Syracuse, New York, United States, 13210 Neurological Care of Central NY Syracuse, New York, United States, 13210 United States, North Carolina Duke University Durham, North Carolina, United States, 27705 United States, Pennsylvania Neurology Associates Monroeville, Pennsylvania, United States, 15146 University of Pittsburg Pittsburg, Pennsylvania, United States, 15213 United States, Texas University of Texas Southwestern Dallas, Texas, United States, 75390 University of Texas Medical School Houston, Texas, United States, 77030 Scott & White Hospital Temple, Texas, United States, 76508 Less <<
NCT01229332 Parkinson's Disease Phase 1 Phase 2 Completed - Israel ... More >> Hadassah Medical Center Jerusalem, Israel Less <<
NCT00829439 Angelman Syndrome Phase 1 Completed - United States, Massachusetts ... More >> Children's Hospital Boston Boston, Massachusetts, United States, 02115 Less <<
NCT01296464 Parkinson's Disease PHASE2 COMPLETED 2025-07-11 Kanta-H?meen keskussairaala, H... More >>?meenlinna, 13530, Finland|ODL Terveys Oy (ODL), Oulu, 90100, Finland|Porin L??k?ritalo, Pori, 28100, Finland|L?nssjukhuset Ryhov, Medicin/Neurologmottagningen, J?nk?ping, SE-55185, Sweden|Karolinska Universitetssjukhuset Solna, Neurologkliniken, Stockholm, SE-171 76, Sweden Less <<
NCT03023059 Age-related Macular Degenerati... More >>on Less << Phase 2 Recruiting February 2019 United States, Arizona ... More >> Robert W Snyder, MD, PhD, PC Recruiting Tucson, Arizona, United States, 85712 Contact: Timothy C Fagan, MD    520-404-5801    tcfaganmd@gmail.com    Contact: Robert W Snyder, MD    (520) 661-6516    rsnyder781@gmail.com Less <<
NCT00829439 - Completed - -
NCT01399905 Parkinson's Disease Phase 2 Completed - United States, Oregon ... More >> Oregon Health & Science University Portland, Oregon, United States, 97239 Less <<
NCT01212484 Familial Dysautonomia Phase 3 Completed - -
NCT01212484 - Completed - -
NCT02486432 Parkinson's Disease Phase 1 Completed - -
NCT02386475 Stroke Phase 4 Recruiting December 30, 2018 Spain ... More >> Granollers General Hospital Recruiting Granollers, Barcelnoa, Spain, 08402 Contact: Dolores Cocho, M.D.    938425000    dcocho@fhag.es    Contact: diana navarro, Ph. D.    938425000    diananavarro@fhag.es    Principal Investigator: Dolores Cocho, M.D. Less <<
NCT00406029 - Completed - -
NCT00406029 Parkinson Disease ... More >> Movement Disorders Central Nervous System Diseases Neurodegenerative Diseases Brain Diseases Less << Phase 2 Completed - -
NCT00024622 - Recruiting - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov Less <<
NCT02696512 Brain Injury Phase 1 Phase 2 Unknown April 2017 United States, New Jersey ... More >> International Brain Research Foundation Recruiting Edison, New Jersey, United States, 08837 Contact: Philip Defina, PhD    732-494-7600    pdefina@ibrfinc.org    Principal Investigator: Philip Defina, PhD Less <<
NCT02994719 - Recruiting October 2019 United States, Massachusetts ... More >> Clinical Research Center BIDMC Recruiting Boston, Massachusetts, United States, 02215 Less <<
NCT00537017 Parkinson Disease ... More >> Neurodegenerative Diseases Central Nervous System Diseases Movement Disorders Brain Diseases Less << Phase 2 Completed - -
NCT00537017 - Completed - -
NCT01646255 Idiopathic Parkinson's Disease Phase 3 Completed - China ... More >> Sp1037 001 Beijing, China Sp1037 002 Beijing, China Sp1037 019 Beijing, China Sp1037 025 Beijing, China Sp1037 017 Changchun, China Sp1037 007 Chengdu, China Sp1037 027 Chengdu, China Sp1037 021 Fuzhou, China Sp1037 010 Guangzhou, China Sp1037 011 Guangzhou, China Sp1037 014 Guangzhou, China Sp1037 015 Guangzhou, China Sp1037 005 Hangzhou, China Sp1037 013 Hangzhou, China Sp1037 018 Hangzhou, China Sp1037 023 Jinan, China Sp1037 003 Shanghai, China Sp1037 004 Shanghai, China Sp1037 009 Shanghai, China Sp1037 008 Suzhou, China Sp1037 016 Tianjin, China Sp1037 006 Wuhan, China Sp1037 022 Wuhan, China Sp1037 024 Wuhan, China Less <<
NCT00880620 Parkinson's Disease Phase 3 Completed - -
NCT01096186 Parkinson's Disease Phase 3 Completed - -
NCT01096186 - Completed - -
NCT01568073 Parkinson's Disease Phase 3 Completed - Portugal ... More >> Bial - Portela & Cª, S.A. S. Mamede do Coronado, Portugal, 4745-457 Less <<
NCT01291537 Parkinson's Disease Phase 2 Completed - France ... More >> CH d'Aix en Provence Aix en Provence, France, 13616 Chu Amiens Amiens, France Chu Clermont-Ferrand Clermont-ferrand, France, 63003 Hôpital Henri Mondor Creteil, France, 94010 Chu Lille Lille, France, 59037 Chu de Limoges Limoges, France, 87000 Chu de Lyon Lyon, France, 69229 Chu de Marseille Marseille, France, 13354 Chu de Nantes Nantes, France, 44035 Chu de Nice Nice, France, 06003 Chu de Nimes Nimes, France, 30029 Ch Saint Antoine Paris, France, 75571 Ch La Pitie Salpetriere Paris, France, 75651 Chu de Poitiers Poitiers, France, 86021 Chu de Rennes Rennes, France, 35033 Chu de Rouen Rouen, France, 76031 Chu Saint Etienne Saint Etienne, France, 42055 Chu de Strasbourg Strasbourg, France, 67091 Chu Bordeaux Talence, France, 33404 Chu de Toulouse Toulouse, France, 31059 Less <<
NCT01646255 - Completed - -
NCT00282152 - Completed - -
NCT01747655 - Completed - -
NCT00880620 - Completed - -
NCT01747655 - Completed - -
NCT03243552 ASD Phase 2 Not yet recruiting June 2022 -
NCT01568073 - Completed - -
NCT02906488 - Recruiting January 31, 2021 -
NCT00282152 Parkinson's Disease Not Applicable Completed - -
NCT02274324 Parkinson Disease Not Applicable Unknown December 2017 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.42mL

0.88mL

0.44mL

22.10mL

4.42mL

2.21mL

44.20mL

8.84mL

4.42mL

References

 

Historical Records

Categories